Background, Surfomer (alpha -olefin maleic acid) reduces intestinal cholesterol absorption. Aims. This study was performed to investigate the effect of surfomer on cholesterol synthesis and low density lipoprotein in hamsters fed a hypercholesterolaemic, lipid-enriched diet. Animals and methods. Male hamsters were fed a diet enriched in cholesterol (0.07%) and saturated fatty acids (coconut oil 20%); the diet was supplemented with 3% surfomer: for 1-4 weeks. Cholesterol synthesis was assessed measuring incorporation of [H-3]water into tissue sterols; low density lipoprotein clearance was determined using a primed-continuous infusion of [I-125]tyramine-cellobiose lipoprotein. Results. Cholesterol synthesis was suppressed after 3 weeks of hyperlipidaemic diet in liver and small bowel (by 88% and 38%, respectively) and was significantly increased by supplementing the fat-enriched diet with surfomer. Low density lipoprotein-cholesterol was increased by 44% after 4 weeks of hyperlipidaemic diet, in parallel with a decrease in hepatic low density lipoprotein clearance rates (48 +/-3 vs 68 +/-7 mul of plasma/h per g of tissue). Concurrent treatment with surfomer for 1, P or 4 weeks prevented the decrease of clearance and maintained normal low density lipoprotein-cholesterol levels at all time points, Conclusions. Surfomer represents a powerful tool to investigate the impact of cholesterol absorption on sterol homeostasis. Furthermore, since surfomer appears to normalize low density lipoprotein transport in hamsters fed a diet comparable to a lipid-rich western-style regimen, this drug may deserve consideration as an adjunct treatment for hypercholesterolaemia in selected patient groups.
Inhibition of intestinal cholesterol absorption by surfomer [alpha-olefin maleic acid] affects hepatic cholesterol synthesis and low density lipoprotein transport in hamsters fed a fat-enriched diet / Bertolotti, Marco; Dk, Spady. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 33:2(2001), pp. 145-150. [10.1016/s1590-8658(01)80070-0]
Inhibition of intestinal cholesterol absorption by surfomer [alpha-olefin maleic acid] affects hepatic cholesterol synthesis and low density lipoprotein transport in hamsters fed a fat-enriched diet
BERTOLOTTI, Marco;
2001
Abstract
Background, Surfomer (alpha -olefin maleic acid) reduces intestinal cholesterol absorption. Aims. This study was performed to investigate the effect of surfomer on cholesterol synthesis and low density lipoprotein in hamsters fed a hypercholesterolaemic, lipid-enriched diet. Animals and methods. Male hamsters were fed a diet enriched in cholesterol (0.07%) and saturated fatty acids (coconut oil 20%); the diet was supplemented with 3% surfomer: for 1-4 weeks. Cholesterol synthesis was assessed measuring incorporation of [H-3]water into tissue sterols; low density lipoprotein clearance was determined using a primed-continuous infusion of [I-125]tyramine-cellobiose lipoprotein. Results. Cholesterol synthesis was suppressed after 3 weeks of hyperlipidaemic diet in liver and small bowel (by 88% and 38%, respectively) and was significantly increased by supplementing the fat-enriched diet with surfomer. Low density lipoprotein-cholesterol was increased by 44% after 4 weeks of hyperlipidaemic diet, in parallel with a decrease in hepatic low density lipoprotein clearance rates (48 +/-3 vs 68 +/-7 mul of plasma/h per g of tissue). Concurrent treatment with surfomer for 1, P or 4 weeks prevented the decrease of clearance and maintained normal low density lipoprotein-cholesterol levels at all time points, Conclusions. Surfomer represents a powerful tool to investigate the impact of cholesterol absorption on sterol homeostasis. Furthermore, since surfomer appears to normalize low density lipoprotein transport in hamsters fed a diet comparable to a lipid-rich western-style regimen, this drug may deserve consideration as an adjunct treatment for hypercholesterolaemia in selected patient groups.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris